proud-pv and mpd-rc 112 trials of interferon alpha vs hydroxyurea for mpns
Published 7 years ago • 838 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
1:59
mpd-rc 112 trial of pegylated interferon alpha-2a for polycythemia vera & essential thrombocythemia
-
2:02
conti-pv: a 2-year follow-up of interferon product aop2014
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
2:05
ropeg in polycythemia vera: long-term proud-pv and conti-pv results
-
3:00
ropeginterferon alpha-2b as an effective treatment against pv
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
6:01
pureprp® supraphysiologic protein rich platelet rich plasma 60ml
-
32:29
current developments in polycythemia vera treatment: is it curable?
-
4:01
platelet rich plasma (prp) injections: fernando manalac, md
-
2:44
solutions for your molecular genetic diagnostic routine
-
1:35
proud-pv/continuation-pv studies: benefits of ropeg ifn alfa-2b for the treatment of pv
-
2:54
pt-1 study update: addition of hydroxyurea to aspirin in essential thrombocythemia
-
44:46
aplastic anemia, diagnosis and management - haematology - copm weekly webinar 24
-
1:09:44
approach to hemolytic anemia - copm weekly webinar - haematology
-
1:05
covalent-101: bmf-219 in patients with r/r aml, dlbcl & multiple myeloma
-
1:22
ame minute: why did the faa change policy for primary hemochromatosis?
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
4:01
platelet-rich plasma for the knee (part 2/5) | joint ventures (orthosports)
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml